Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

Truvada for PrEP Not Linked to Kidney Impairment, Resistance Is Rare

Truvada (tenofovir/emtricitabine) used for pre-exposure prophylaxis (PrEP) was not associated with clinically relevant declines in kidney function through 36 months in a large clinical trial, researchers recently reported. A related study found that drug resistance is rare among PrEP users, but it can occur in people who have acute HIV infection when they start Truvada and those who become infected despite PrEP.

alt

Read more:

Long-acting Injectable Cabotegravir Shows Promise as PrEP in Monkey Studies

A long-acting injected formulation of the HIV integrase inhibitor cabotegravir (GSK1265744) prevented infection of most macaque monkeys vaginally exposed to an HIV-like hybrid virus at drug concentrations achievable with monthly dosing, according to a pair of studies published in the January 14 issue of Science Translational Medicine.

alt

Read more:

1. HIV PrEP: Rising Use, Promising New Truvada Data, More Future Options

PrEP, or pre-exposure prophylaxis to prevent HIV infection, was the major HIV topic in the mainstream media in 2014. 

alt

Read more:

HIV PrEP Forum Discusses Research, Personal Experiences, and Access

Nearly 100 people gathered on January 11 in San Francisco's Castro neighborhood to learn about the latest research on HIV pre-exposure prophylaxis -- better known as PrEP -- and how they can get help paying for it.

alt

Read more:

No New HIV Infections Seen Among San Francisco Kaiser PrEP Users

No new HIV infections have occurred among more than 500 Kaiser Permanente San Francisco members using pre-exposure prophylaxis -- better known as PrEP -- but condom use appears to be declining among a subset of gay men, according to a small survey presented at a December 1 forum commemorating World AIDS Day.

alt

Read more: